Alexander C Egilman
Overview
Explore the profile of Alexander C Egilman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daval C, Egilman A, Sarpatwari A, Kesselheim A
JAMA
. 2024 May;
331(23):2029-2036.
PMID: 38767878
Importance: The Federal Trade Commission's (FTC) oversight role in the pharmaceutical market is critical to the health of patients and the health care system. This study characterized the FTC's policy...
2.
Egilman A, Kesselheim A, Sarpatwari A, Rome B
Ann Intern Med
. 2024 Apr;
177(6):833-835.
PMID: 38684101
No abstract available.
3.
Egilman A, Kesselheim A, Avorn J, Raymakers A, Rome B
JAMA Dermatol
. 2024 Feb;
160(4):409-416.
PMID: 38381418
Importance: The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles. The efficiency frontier (EF) method offers policymakers an...
4.
Egilman A, Rome B, Kesselheim A
JAMA
. 2023 Aug;
330(7):665-666.
PMID: 37581674
No abstract available.
5.
Egilman A, Rome B, Kesselheim A
JAMA
. 2023 Apr;
329(15):1283-1289.
PMID: 37071095
Importance: The Inflation Reduction Act of 2022 authorizes Medicare to negotiate prices of top-selling drugs based on several factors, including therapeutic benefit compared with existing treatment options. Objective: To determine...
6.
Rome B, Nagar S, Egilman A, Wang J, Feldman W, Kesselheim A
JAMA Health Forum
. 2023 Jan;
4(1):e225218.
PMID: 36705916
Importance: The Inflation Reduction Act of 2022 gives Medicare the authority to negotiate prices for certain prescription drugs. Which drugs will be selected and how prices will be negotiated remain...
7.
Egilman A, Kesselheim A, Rome B
JAMA
. 2023 Jan;
329(1):89-92.
PMID: 36594954
No abstract available.
8.
Egilman A, Van de Wiele V, Rome B, Darrow J, Tu S, Kesselheim A, et al.
JAMA Intern Med
. 2022 Nov;
183(1):82-84.
PMID: 36441536
No abstract available.
9.
Rome B, Egilman A, Patel N, Kesselheim A
Value Health
. 2022 Oct;
26(3):370-377.
PMID: 36266218
Objectives: Brand-name drug manufacturers can market or license authorized generics (AGs), which are the same product sold under a generic name. By contrast, independent generics (IGs) are made by other...
10.
Rome B, Egilman A, Kesselheim A
JAMA
. 2022 Oct;
328(13):1352-1353.
PMID: 36194222
No abstract available.